Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Assay Kit / ADA/PK Assay Elisa Kit

Zanolimumab ELISA Kit

Catalog #:   KDB95903 Specific References (25) DATASHEET
Applications: Used for the quantitative determination of Zanolimumab concentration in serum and plasma.
Sample type: Plasma, Serum
Sensitivity: 80.12 ng/mL
Range: 156.25 - 10,000 ng/mL
Overview

Catalog No.

KDB95903

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD4 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Zanolimumab in the sample competitively binds to the pre-coated protein with biotin-labeled Zanolimumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Zanolimumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Zanolimumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

156.25 - 10,000 ng/mL

Sensitivity

80.12 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

 

Intra-Assay Precision

Inter-Assay Precision

Sample

1

2

3

1

2

3

n

16

16

16

24

24

24

Mean (ng/mL)

6426.4

1304.6

330.4

5624.2

1380.2

292.4

Standard deviation

774.4

150.5

37.7

463.8

138.1

34.4

CV (%)

12.1

11.5

11.4

8.2

10.0

11.8

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

HuMax-CD4, CAS: 652153-01-0

Background

Zanolimumab is a biosimilar that targets CD4. The CD4 antigen is involved in the recognition of MHC class II molecules and is a co-receptor for HIV. CD4 is primarily expressed in a subset of T-lymphocytes, also referred to as T helper cells, but may also be expressed by other cells in the immune system, such as monocytes, macrophages, and dendritic cells. At the tissue level, CD4 expression may be detected in thymus, lymph nodes, tonsils, and spleen, and also in specific regions of the brain, gut, and other non-lymphoid tissues. CD4 functions to initiate or augment the early phase of T-cell activation through its association with the T-cell receptor complex and protein tyrosine kinase, Lck. It may also function as an important mediator of direct neuronal damage in infectious and immune-mediated diseases of the central nervous system. Multiple alternatively spliced transcripts have been identified in this gene [RefSeq, July 2017].

Data Image
  • Experiment Example
    CALCULATION OF RESULTS
    Average the duplicate readings for each standard and sample. Construct a standard curve by plotting the mean absorbance for each standard on the Y-axis against the concentration on the X-axis and draw a best fit curve through the points on the graph. Do not include the blank in the standard curve. The data may be linearized by plotting the log of the Zanolimumab concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.
References

[Primary skin lymphomas: Current therapy]., PMID:30709635

Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease., PMID:29102679

Peripheral T-cell lymphomas: a review of current approaches and hopes for the future., PMID:23755375

Alemtuzumab-resistant Sézary syndrome responding to zanolimumab., PMID:21480857

New antibody drug treatments for lymphoma., PMID:21395497

Antibody-based therapeutics to watch in 2011., PMID:21051951

Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma., PMID:20629661

Novel antibodies in the treatment of non-Hodgkin's lymphoma., PMID:19767657

[Biotherapy of auto-immune diseases : past, present and future perspectives]., PMID:19303737

Molecular biology and targeted therapy of cutaneous T-cell lymphomas., PMID:19169209

Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome., PMID:18990079

Novel therapies in peripheral T-cell lymphomas., PMID:18706268

Novel human antibody therapeutics: the age of the Umabs., PMID:18702090

Newer monoclonal antibodies for hematological malignancies., PMID:18565392

Gateways to clinical trials., PMID:18560631

Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development., PMID:18433608

A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity., PMID:17942927

Cutaneous T-cell lymphoma: Biologic targets for therapy., PMID:20425380

A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development., PMID:17763605

Drug evaluation: zanolimumab, a human monoclonal antibody targeted against CD4., PMID:17458175

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma., PMID:17311990

In situ depletion of CD4+ T cells in human skin by Zanolimumab., PMID:17091277

Gateways to clinical trials., PMID:16810345

Gateways to clinical trials., PMID:16541195

Gateways to clinical trials., PMID:16082422

Datasheet

Document Download

Zanolimumab ELISA Kit.pdf

 

$ 1128
Product specifications
96 T 1128

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Zanolimumab ELISA Kit [KDB95903]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only